

Next Day Disclosure Return
(Equity issuer - changes in issued share capital and/or share buybacks)

Instrument: Equity issuer Status: New Submission
Name of Issuer: Charmacy Pharmaceutical Co., Ltd.
Date Submitted: 29 June 2022

Section I must be completed by a listed issuer where there has been a change in its issued share capital which is discloseable pursuant to rule 13.25A of the Main Board Rules (the "Main Board Listing Rules") / rule 17.27A of the GEM Rules (the "GEM Listing Rules") Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Exchange")

Section I						
1. Type of shares	Ordinary shares	Class of shares	Class H	Listed on SEHK (Note 11)	Yes	
Stock code (if listed)	02289	Description	H Shares			
Issues of shares (Notes 6 and 7)	No. of shares	Issued shares as a % of existing number of issued shares before relevant share issue (Notes 4, 6 and 7)	Issue price per share (Notes 1 and 7)	Closing market price per share of the immediately preceding business day (Note 5)	% discount(-)/ premium of issue price to market price (Note 7)	
Opening balance as at (Note 2) 31 May 2022	28,000,000					
1). Other (please specify) Conversion of 80,000,000 unlisted domestic shares into 80,000,000 H shares (the "Conversion") Date of changes 29 June 2022	80,000,000	285.71 %		HKD 8	%	
Closing balance as at (Note 8) 29 June 2022	108,000,000					

2. Type of shares	Ordinary shares	Class of shares	Other class (specify in description)	Listed on SEHK (Note 11)	No	
Stock code (if listed)		Description	Domestic Shares			

Issues of shares (Notes 6 and 7)	No. of shares	Issued shares as a % of existing number of issued shares before relevant share issue (Notes 4, 6 and 7)	Issue price per share (Notes 1 and 7)	Closing market price per share of the immediately preceding business day (Note 5)	% discount(-)/ premium of issue price to market price (Note 7)
Opening balance as at (Note 2) 31 May 2022	80,000,000				
1). Other (please specify) The Conversion Date of changes 29 June 2022	-80,000,000	%			%
Closing balance as at (Note 8) 29 June 2022	0				

Remarks:

Charmacy Pharmaceutical Co., Ltd. (the "Company") has received the formal approval from the China Securities Regulatory Commission on 6 June 2022, as disclosed in the announcement of the Company dated 6 June 2022, and the approval from The Stock Exchange of Hong Kong Limited (the "Stock Exchange") on 14 June 2022, as disclosed in the announcement of the Company dated 15 June 2022, of the conversion of up to an aggregate of 80,000,000 unlisted domestic shares of the Company ("Domestic Shares") into H shares of the Company ("H Shares") and their listing thereof on the Stock Exchange. The conversion and listing were completed on 29 June 2022, as disclosed in the announcement of the Company dated 29 June 2022.

Immediately before completion of the conversion and listing, the total number of issued shares of the Company was 108,000,000 shares (including 80,000,000 Domestic Shares and 28,000,000 H Shares). Upon completion of the conversion and listing, H Shares increased by 80,000,000 shares, while Domestic Shares decreased by 80,000,000 shares. The total number of issued shares of the Company remains unchanged.

We hereby confirm to the best knowledge, information and belief that, in relation to each issue of securities as set out in Section I, it has been duly authorised by the board of directors of the listed issuer and, insofar as applicable:

(Note 9)

- (i) all money due to the listed issuer in respect of the issue of securities has been received by it;
- (ii) all pre-conditions for the listing imposed by the Main Board Listing Rules / GEM Listing Rules under "Qualifications of listing" have been fulfilled;
- (iii) all (if any) conditions contained in the formal letter granting listing of and permission to deal in the securities have been fulfilled;
- (iv) all the securities of each class are in all respects identical (Note 10);
- (v) all documents required by the Companies (Winding Up and Miscellaneous Provisions) Ordinance to be filed with the Registrar of Companies have been duly filed and that compliance has been made with other legal requirements;
- (vi) all the definitive documents of title have been delivered/are ready to be delivered/are being prepared and will be delivered in accordance with the terms of issue;
- (vii) completion has taken place of the purchase by the issuer of all property shown in the listing document to have purchased or agreed to be purchased by it and the purchase consideration for all such property has been duly satisfied; and
- (viii) the trust deed/deed poll relating to the debenture, loan stock, notes or bonds has been completed and executed, and particulars thereof, if so required by law, have been filed with the Registrar of Companies.

Notes to Section I:

1. *Where shares have been issued at more than one issue price per share, a weighted average issue price per share should be given.*
2. *Please insert the closing balance date of the last Next Day Disclosure Return published pursuant to Main Board Rule 13.25A / GEM Rule 17.27A or Monthly Return pursuant to Main Board Rule 13.25B / GEM Rule 17.27B, whichever is the later.*
3. *Please set out all changes in issued share capital requiring disclosure pursuant to Main Board Rule 13.25A / GEM Rule 17.27A together with the relevant dates of issue. Each category will need to be disclosed individually with sufficient information to enable the user to identify the relevant category in the listed issuer's Monthly Return. For example, multiple issues of shares as a result of multiple exercises of share options under the same share option scheme or of multiple conversions under the same convertible note must be aggregated and disclosed as one category. However, if the issues resulted from exercises of share options under 2 share option schemes or conversions of 2 convertible notes, these must be disclosed as 2 separate categories.*
4. *The percentage change in the number of issued shares of listed issuer is to be calculated by reference to the listed issuer's total number of shares in issue (excluding for such purpose any shares repurchased or redeemed but not yet cancelled) as it was immediately before the earliest relevant event which has not been disclosed in a Monthly Return or Next Day Disclosure Return.*
5. *Where trading in the shares of the listed issuer has been suspended, "closing market price per share of the immediately preceding business day" should be construed as "closing market price per share of the business day on which the shares were last traded".*
6. *In the context of a repurchase of shares:*
 - *"issues of shares" should be construed as "repurchases of shares"; and*

- *“issued shares as a % of existing number of shares before relevant share issue” should be construed as “repurchased shares as a % of existing number of shares before relevant share repurchase”.*

7. *In the context of a redemption of shares:*

- *“issues of shares” should be construed as “redemptions of shares”;*
- *“issued shares as a % of existing number of shares before relevant share issue” should be construed as “redeemed shares as a % of existing number of shares before relevant share redemption”; and*
- *“issue price per share” should be construed as “redemption price per share”.*

8. *The closing balance date is the date of the last relevant event being disclosed.*

9. *Items (i) to (viii) are suggested forms of confirmation which may be amended to meet individual cases.*

10. *“Identical” means in this context:*

- *the securities are of the same nominal value with the same amount called up or paid up;*
- *they are entitled to dividend/interest at the same rate and for the same period, so that at the next ensuing distribution, the dividend/interest payable per unit will amount to exactly the same sum (gross and net); and*
- *they carry the same rights as to unrestricted transfer, attendance and voting at meetings and rank pari passu in all other respects.*

11. *SEHK refers to Stock Exchange of Hong Kong.*

Section II must also be completed by a listed issuer where it has made a repurchase of shares which is discloseable under Main Board Rule 10.06(4)(a) / GEM Rule 13.13(1).

The issuer has Purchase report or additional information for issuer whose primary listing is on the Exchange Not applicable

Submitted by: Yao Jiexi

(Name)

Title: Joint Company Secretary

(Director, Secretary or other Duly Authorised Officer)